234 related articles for article (PubMed ID: 15080792)
21. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylation of Thr654 but not Thr669 within the juxtamembrane domain of the EGF receptor inhibits calmodulin binding.
Aifa S; Frikha F; Miled N; Johansen K; Lundström I; Svensson SP
Biochem Biophys Res Commun; 2006 Aug; 347(2):381-7. PubMed ID: 16793002
[TBL] [Abstract][Full Text] [Related]
23. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
25. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
26. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
[TBL] [Abstract][Full Text] [Related]
27. HER-2/c-erbB2 is phosphorylated by calmodulin-dependent protein kinase II on a single site in the cytoplasmic tail at threonine-1172.
Feinmesser RL; Gray K; Means AR; Chantry A
Oncogene; 1996 Jun; 12(12):2725-30. PubMed ID: 8700533
[TBL] [Abstract][Full Text] [Related]
28. The activating role of phospho-(Tyr)-calmodulin on the epidermal growth factor receptor.
Stateva SR; Salas V; Benguría A; Cossío I; Anguita E; Martín-Nieto J; Benaim G; Villalobo A
Biochem J; 2015 Dec; 472(2):195-204. PubMed ID: 26399481
[TBL] [Abstract][Full Text] [Related]
29. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
[TBL] [Abstract][Full Text] [Related]
30. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
31. The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility.
Roovers K; Wagner S; Storbeck CJ; O'Reilly P; Lo V; Northey JJ; Chmielecki J; Muller WJ; Siegel PM; Sabourin LA
Oncogene; 2009 Aug; 28(31):2839-48. PubMed ID: 19525980
[TBL] [Abstract][Full Text] [Related]
32. Thrombin-mediated ET-1 gene regulation involves CaM kinases and calcineurin in human endothelial cells.
Marsen TA; Simonson MS; Dunn MJ
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S1-4. PubMed ID: 8587330
[TBL] [Abstract][Full Text] [Related]
33. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
34. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
Tari AM; Hung MC; Li K; Lopez-Berestein G
Oncogene; 1999 Feb; 18(6):1325-32. PubMed ID: 10022814
[TBL] [Abstract][Full Text] [Related]
35. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
36. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
37. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
38. Induction or suppression of expression of cytochrome C oxidase subunit II by heregulin beta 1 in human mammary epithelial cells is dependent on the levels of ErbB2 expression.
Sun Y; Lin H; Zhu Y; Ma C; Ye J; Luo J
J Cell Physiol; 2002 Aug; 192(2):225-33. PubMed ID: 12115729
[TBL] [Abstract][Full Text] [Related]
39. Heregulinbeta activates store-operated Ca2+ channels through c-erbB2 receptor level-dependent pathway in human breast cancer cells.
Liao JY; Li LL; Wei Q; Yue JC
Arch Biochem Biophys; 2007 Feb; 458(2):244-52. PubMed ID: 17214955
[TBL] [Abstract][Full Text] [Related]
40. Ca2+/calmodulin-dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal generation.
Feinmesser RL; Wicks SJ; Taverner CJ; Chantry A
J Biol Chem; 1999 Jun; 274(23):16168-73. PubMed ID: 10347170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
